ZA200803454B - Piperazine derivatives useful as CCR5 antagonists - Google Patents

Piperazine derivatives useful as CCR5 antagonists

Info

Publication number
ZA200803454B
ZA200803454B ZA200803454A ZA200803454A ZA200803454B ZA 200803454 B ZA200803454 B ZA 200803454B ZA 200803454 A ZA200803454 A ZA 200803454A ZA 200803454 A ZA200803454 A ZA 200803454A ZA 200803454 B ZA200803454 B ZA 200803454B
Authority
ZA
South Africa
Prior art keywords
derivatives useful
piperazine derivatives
ccr5 antagonists
ccr5
antagonists
Prior art date
Application number
ZA200803454A
Other languages
English (en)
Inventor
Ramanthan Ragulan
Michael W Miller
Kevin B Alton
Ghosal Anima
Swapan K Chowdhury
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA200803454B publication Critical patent/ZA200803454B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ZA200803454A 2005-10-21 2008-04-18 Piperazine derivatives useful as CCR5 antagonists ZA200803454B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/255,643 US7825121B2 (en) 1999-05-04 2005-10-21 Piperazine derivatives useful as CCR5 antagonists

Publications (1)

Publication Number Publication Date
ZA200803454B true ZA200803454B (en) 2009-04-29

Family

ID=37872167

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200803454A ZA200803454B (en) 2005-10-21 2008-04-18 Piperazine derivatives useful as CCR5 antagonists

Country Status (17)

Country Link
US (1) US7825121B2 (no)
EP (1) EP1951708B1 (no)
JP (2) JP2009512705A (no)
KR (1) KR20080058486A (no)
CN (1) CN101326178A (no)
AR (1) AR058105A1 (no)
AU (1) AU2006306491B2 (no)
BR (1) BRPI0617731A2 (no)
CA (1) CA2626565A1 (no)
EC (1) ECSP088378A (no)
IL (1) IL190902A0 (no)
NO (1) NO20082297L (no)
PE (1) PE20070711A1 (no)
RU (1) RU2008119652A (no)
TW (1) TW200800234A (no)
WO (1) WO2007050375A2 (no)
ZA (1) ZA200803454B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005101838A2 (en) 2004-04-13 2005-10-27 Incyte Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
CA2626641A1 (en) * 2005-10-21 2007-07-19 Glaxo Group Limited Compounds
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
WO2010081851A1 (en) 2009-01-14 2010-07-22 Genoscience Pharma Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
BR112013023050A8 (pt) 2011-03-09 2018-09-25 G Pestell Richard antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um composto candidato, para produzir in vitro células epiteliais primárias, para diagnosticar câncer de próstata, para selecionar um tratamento para um indivíduo tendo um câncer/tumor de próstata, linhagem de célula, e, modelo animal
GB201118876D0 (en) 2011-11-01 2011-12-14 Astex Therapeutics Ltd Pharmaceutical compounds
CA2873743C (en) * 2012-05-14 2022-12-06 Prostagene, Llc Using modulators of ccr5 for treating cancer
US10301281B2 (en) 2014-12-11 2019-05-28 Merck Sharp & Dohme Corp. Crystal forms of a CCR5 antagonist

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
KR100439358B1 (ko) * 1999-05-04 2004-07-07 쉐링 코포레이션 Ｃｃｒ5 길항제로서 유용한 피페라진 유도체
WO2002079157A1 (en) * 2001-03-29 2002-10-10 Schering Corporation Aryl oxime-piperazines useful as ccr5 antagonists

Also Published As

Publication number Publication date
US7825121B2 (en) 2010-11-02
ECSP088378A (es) 2008-05-30
US20060105964A1 (en) 2006-05-18
AU2006306491B2 (en) 2012-12-13
NO20082297L (no) 2008-07-21
PE20070711A1 (es) 2007-08-11
JP2012072195A (ja) 2012-04-12
AU2006306491A1 (en) 2007-05-03
IL190902A0 (en) 2008-11-03
CA2626565A1 (en) 2007-05-03
WO2007050375A2 (en) 2007-05-03
AR058105A1 (es) 2008-01-23
CN101326178A (zh) 2008-12-17
JP2009512705A (ja) 2009-03-26
TW200800234A (en) 2008-01-01
KR20080058486A (ko) 2008-06-25
RU2008119652A (ru) 2009-11-27
BRPI0617731A2 (pt) 2011-08-02
EP1951708A2 (en) 2008-08-06
EP1951708B1 (en) 2013-11-20
WO2007050375A3 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
ZA200708028B (en) Acetylenyl-pyrazolo-pyrimidine derivatives as mGluR2 antagonists
IL190952A0 (en) Piperazine derivatives as antimalarial agents
IL185326A0 (en) PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS
ZA200710968B (en) Piperidine derivatives useful as histamine H3 antagonists
ZA200803811B (en) Neuropolin antagonists
ZA200800320B (en) Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
IL191907A0 (en) Azepinoindole derivatives as pharmaceutical agents
HK1124233A1 (en) Quinoline derivatives as antibacterical agents
HK1163677A1 (zh) 可用作激酶抑制劑的吡唑基氨基吡啶衍生物
ZA200706353B (en) Pyrazolo-pyrimidine derivatives as mGluR2 antagonists
EP1940412A4 (en) NEW OPIOID ANTAGONISTS
AP2007004047A0 (en) Substituted triazole derivatives as oxtocin antagonists
IL185327A0 (en) PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS
IL179888A0 (en) Compounds as ccr5 antagonists
GB0523609D0 (en) Piperazine derivatives
ZA200806065B (en) Oxazoloisoquinoline derivatives as thrombin receptor antagonists
EP1854446A4 (en) ANTIALLERGIC COMPOSITION
ZA200803454B (en) Piperazine derivatives useful as CCR5 antagonists
IL202339A0 (en) Azacyclylbenzamide derivatives as histamine-3 antagonists
ZA200802339B (en) Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
IL188371A0 (en) Novel piperidine derivatives
EP1931347A4 (en) PIPERAZIN DERIVATIVES
ZA200709230B (en) Novel piperidine derivatives
GB0503043D0 (en) Piperazine derivatives
ZA200800374B (en) Novel piperidine derivatives